SHUBHAM PANT to Antibodies, Bispecific
This is a "connection" page, showing publications SHUBHAM PANT has written about Antibodies, Bispecific.
Connection Strength
0.341
-
Co-clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts. Cancer Discov. 2024 May 01; 14(5):828-845.
Score: 0.179
-
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study. Lancet Oncol. 2022 12; 23(12):1558-1570.
Score: 0.162